香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 於報告期，我們於推進我們的商業化、產品管線及業務運營方面取得重大進展： 商業化 － 本集團截至2025年6月30日止六個月的產品銷售及研發服務收益為人民幣 1,092.0百萬元，較去年同期的人民幣739.7百萬元增長47.6%，主要由本公 司自身免疫類商業化產品泰它西普（RC18，商品名：泰愛®）及抗腫瘤類商 業化產品維迪西妥單抗（RC48，商品名：愛地希®）的強勁銷售增長帶動。 1 產品管線 RemeGen Co., Ltd.* 榮 昌 生 物 製 藥（ 煙 台 ）股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：9995） 截至2025年6月30日止六個月 中期業績公告 董事會欣然宣佈本集團截至2025年6月30日止六個月的未經審核簡明合併中期業 績，連同2024年同期的比較數字。 業務摘要 泰它西普（RC18，商品名：泰愛®） 維迪西妥單抗（RC48，商品名：愛地希® ...

Core Insights - Rongchang Biopharmaceuticals reported a significant increase in revenue for the first half of 2025, with total revenue reaching 1.098 billion yuan, a year-on-year growth of 48.02% [1] - The company experienced a net loss of 450 million yuan, which is a 42.40% increase in losses compared to the previous year [1] - The gross profit margin improved to 84.06%, up 5.79 percentage points year-on-year, while the net profit margin was -40.95%, an increase of 64.27 percentage points from the previous year [1] Financial Performance - The basic earnings per share for the first half of 2025 was -0.83 yuan, with a weighted average return on equity of -23.66% [1] - The company's price-to-earnings ratio (TTM) is approximately -32.39, with a price-to-book ratio of about 25.11 and a price-to-sales ratio of around 23.26 [1] - In Q2 2025, the gross profit margin was 84.79%, showing a year-on-year increase of 5.90 percentage points and a quarter-on-quarter increase of 1.53 percentage points [1] Expense Management - Total operating expenses for the first half of 2025 were 1.365 billion yuan, a decrease of 10.85 million yuan compared to the previous year, with an expense ratio of 124.30%, down 61.15 percentage points year-on-year [2] - Sales expenses increased by 34.93%, while management expenses decreased by 0.91%, and research and development expenses fell by 19.72% [2] - Financial expenses rose by 41.75% compared to the previous year [2] Shareholder Dynamics - As of the end of the first half of 2025, the total number of shareholders increased to 12,900, a rise of 6,136 shareholders or 90.69% from the previous quarter [2] - The average market value of shares held per shareholder decreased from 3.2864 million yuan at the end of the first quarter to 2.6429 million yuan, a decline of 19.58% [2] Company Overview - Rongchang Biopharmaceuticals, established on July 4, 2008, is located in the Yantai Free Trade Zone, Shandong, China, and was listed on March 31, 2022 [3] - The company focuses on innovative biopharmaceuticals, particularly in the fields of antibody-drug conjugates (ADC), antibody fusion proteins, and monoclonal antibodies [3] - The main revenue sources are from biopharmaceuticals (98.97%), with minor contributions from technical services (0.64%) and other sources (0.39%) [3]

格隆汇8月22日丨荣昌生物(688331.SH)公布半年度报告，报告期内，销售收入及销量同比增长强劲，公 司实现营业收入10.98亿元，较去年同期的7.42亿元增加48.02%，归属于上市公司股东的净亏损4.50亿 元，归属于上市公司股东的扣除非经常性损益的净亏损4.46亿元，亏损金额同比大幅下降。 ...

Group 1 - The board of directors of Rongchang Biopharmaceuticals held its 28th meeting, with all 9 directors present, confirming compliance with relevant laws and regulations [1][2] - The board approved the unaudited consolidated financial statements for the six months ending June 30, 2025, which were reviewed by the audit committee [1][3] - The board decided not to declare an interim dividend for 2025, considering the company's overall financial condition and capital needs [2][3] Group 2 - The board approved the company's 2025 interim report and its summary, ensuring compliance with regulations and confirming the accuracy and completeness of the information [2][3] - A special report on the use of raised funds for the first half of 2025 was also approved, with details available on the Shanghai Stock Exchange website [3][5] - The board reviewed and confirmed the effectiveness of the company's risk management and internal control systems for the first half of 2025 [4][5] Group 3 - The board confirmed compliance with the Corporate Governance Code and related rules, with no violations reported during the first half of 2025 [4][5] - An evaluation report on the "Quality Improvement and Efficiency Enhancement" action plan for 2025 was approved, summarizing the execution status for the first half of the year [4][5] - The board approved changes to the registered capital and amendments to the company's articles of association following the issuance of 19 million H shares on May 29, 2025 [5][6] Group 4 - The board reviewed the progress of the company's Environmental, Social, and Governance (ESG) goals for 2025, focusing on sustainable development and social responsibility [5][6]

（文章来源：每日经济新闻） 荣昌生物8月22日晚间发布公告称，公司第二届第二十八次董事会会议于2025年8月22日在公司会议室以 现场结合通讯方式召开。会议审议了《关于<2025年度"提质增效重回报"行动方案的半年度评估报告> 的议案》等文件。 ...

Core Insights - Rongchang Bio reported a revenue of approximately 1.098 billion yuan for the first half of 2025, representing a year-on-year increase of 48.02% [2] - The net loss attributable to shareholders was approximately 450 million yuan, with a basic earnings per share loss of 0.83 yuan [2] - In comparison, the revenue for the same period in 2024 was about 742 million yuan, with a net loss of approximately 780 million yuan and a basic earnings per share loss of 1.45 yuan [2] Financial Performance - Revenue for H1 2025: 1.098 billion yuan, up 48.02% year-on-year [2] - Net loss for H1 2025: 450 million yuan [2] - Basic earnings per share for H1 2025: loss of 0.83 yuan [2] - Revenue for H1 2024: 742 million yuan [2] - Net loss for H1 2024: 780 million yuan [2] - Basic earnings per share for H1 2024: loss of 1.45 yuan [2]

荣昌生物制药（烟台）股份有限公司 章 程 荣昌生物制药（烟台）股份有限公司 2025 年 8 月 | 第一章 | 总则 4 | | | --- | --- | --- | | 第二章 | 经营宗旨和范围 6 | | | 第三章 | 股份 6 | | | 第一节 | 股份发行 | 6 | | 第二节 | 股份增减和回购 | 7 | | 第三节 | 股份转让 | 8 | | 第四章 | 股东和股东会 9 | | | 第一节 | 股东的一般规定 | 9 | | 第二节 | 控股股东和实际控制人 | 12 | | 第三节 | 股东会的一般规定 | 13 | | 第四节 | 股东会的召集 | 15 | | 第五节 | 股东会的提案与通知 | 17 | | 第六节 | 股东会的召开 | 18 | | 第七节 | 股东会的表决和决议 | 21 | | 第五章 | 董事和董事会 24 | | | 第一节 | 董事的一般规定 | 24 | | 第二节 | 董事会 | 28 | | 第三节 | 独立董事 | 32 | | 第四节 | 董事会专门委员会 | 36 | | 第六章 | 高级管理人员 38 | | | 第七章 | 财务 ...

| 证券代码：688331 | 证券简称：荣昌生物 | 公告编号：2025-041 | | --- | --- | --- | | 港股代码：09995 | 港股简称：榮昌生物 | | | 《公司章程》原条款 | 《公司章程》修订后的条款 | | --- | --- | | 第六条 公司的注册资本为人民币 | 第六条 公司的注册资本为人民币 | | 54,460.8243万元。 | 56,360.8243万元。 | | 第二十一条 公司已发行的股份总数为 | 第二十一条 公司已发行的股份总数为 | | 544,608,243 股普 通股， 其中 A股为 | 563,608,243股普通股，其中A股为 | | 355,027,004 股 ， 约 占 股 本 总 数 的 | 355,027,004 股 ， 约 占 股 本 总 数 的 | | 65.19%，H股为189,581,239股，约占 | 62.99%，H股为208,581,239股，约占 | | 股本总数的34.81%。 | 股本总数的37.01%。 | 除上述条款修订外，《公司章程》其他条款不变。上述内容的变更最终以工商登 记机关核准的内容为准，修订后 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据中国证券监督管理委员会发布的《上市公司监管指引第 2 号——上市公 司募集资金管理和使用的监管要求》和上海证券交易所颁布的《上海证券交易所 科创板上市公司自律监管指引第 1 号——规范运作》等的相关规定，荣昌生物制 药（烟台）股份有限公司（以下简称"公司"）将 2025 年上半年募集资金存放 与使用情况报告如下： 一、募集资金基本情况 | 证券代码：688331 | 证券简称：荣昌生物 | 公告编号：2025-040 | | --- | --- | --- | | 港股代码：09995 | 港股简称：榮昌生物 | | 荣昌生物制药（烟台）股份有限公司 2025年半年度募集资金存放与实际使用情况的专项报告 （一）实际募集资金金额及资金到账情况 经中国证券监督管理委员会《关于同意荣昌生物制药（烟台）股份有限公司 首次公开发行股票注册的批复》（证监许可[2022]62 号）核准，公司首次公开 发行人民币普通股（A 股）股票 5,442.6301 万股，发行价格为每股 48 元。 ...

荣昌生物制药（烟台）股份有限公司 关于公司 2025 年度"提质增效重回报"行动方案的半 年度评估报告 为推动提升荣昌生物制药（烟台）股份有限公司（以下简称"公 司"）投资价值，践行以"投资者为本"的上市公司发展理念，维护公 司全体股东利益，增强投资者信心，促进公司长远健康可持续发展， 公司于 2025 年 3 月 28 日发布了《2025 年度"提质增效重回报"行动方 案》（以下简称"行动方案"）。2025 年上半年，公司根据行动方案内容， 积极开展和落实各项工作，现将报告期内的主要措施落实（进展）及 成效情况报告如下： 公司根据行动方案内容，积极开展和落实各项工作，新药研发管 线持续推进，多个创新药物处于关键试验研究阶段，同时泰它西普和 维迪西妥单抗销售快速增长，营业收入稳步提升。 2025 年上半年，公司实现营业收入 10.98 亿元，较去年增长 48%； 综合毛利率为 84.0%，较去年同期提高 5.8 个百分点；销售费用率为 47.9%，较去年同期下降了 4.6 个百分点，随着销售规模的扩大，销 售费用率呈下降趋势。一季度亏损 2.5 亿元，二季度亏损 1.9 亿元， 亏损环比下降 24.8%，上半 ...